DexCom, Inc.’s Stock Price Soars to $75.11, Marking a Robust 2.36% Increase in Value

DexCom, Inc. (DXCM)

75.11 USD +1.73 (+2.36%) Volume: 3.59M

Explore DexCom, Inc.’s stock price, currently standing at 75.11 USD, showcasing a positive change of +2.36% in this trading session with a significant trading volume of 3.59M. Despite the recent uptick, DXCM shares have witnessed a -3.42% decrease year-to-date, highlighting its dynamic performance in the market.

Latest developments on DexCom, Inc.

Dexcom Inc. (DXCM) continues to make waves in the stock market, with its shares outperforming competitors on a strong trading day. The company recently shared 15-day CGM data, showcasing its game-changing Continuous Glucose Monitoring (CGM) technology which achieved an industry-best 8.0% Mean Absolute Relative Difference (MARD). This success has caught the attention of healthcare professionals, as a report unveiled at ATTD 2025 revealed that doctors are increasingly choosing tech over medication for the future of Type 2 care. Additionally, Dexcom welcomed Renée Galá to its Board of Directors, further solidifying its position as one of the best diabetes stocks to buy, as endorsed by billionaires.

DexCom, Inc. on Smartkarma

Analyst coverage of Dexcom Inc on Smartkarma by Baptista Research highlights the company’s strategic growth and investment initiatives. In their report titled “Dexcom Inc.: Will Sensor Tech Advancements Solidify Its Lead In Continuous Glucose Monitoring?”, DexCom Inc’s latest earnings for the fourth quarter of 2024 show an 8% organic revenue growth year-over-year and a 25% increase in the customer base to over 2.8 million globally. This positive performance aligns with the company’s guidance and expectations, positioning Dexcom as a key player in the continuous glucose monitoring market.

Furthermore, Baptista Research delves deeper into Dexcom’s performance in their report “DexCom Inc.: These Are The 7 Biggest Factors Driving Its Performance In 2025 & Beyond! – Major Drivers”. The report discusses the company’s recent third-quarter 2024 earnings call, highlighting both achievements and challenges faced by Dexcom in the glucose monitoring technology sector. With a mixed outlook on market dynamics, investors are advised to carefully evaluate the company’s strategic and operational updates. Baptista Research aims to provide an independent valuation of Dexcom using a Discounted Cash Flow (DCF) methodology to assess the company’s potential price movements in the near future.

A look at DexCom, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Dexcom Inc has a promising long-term outlook. With a high Growth score of 5, the company is expected to see significant expansion and development in the future. This indicates a positive trajectory for Dexcom Inc in terms of market growth and potential.

Additionally, Dexcom Inc also scores well in Momentum with a score of 4, suggesting that the company is experiencing strong positive momentum in the market. This indicates that Dexcom Inc is likely to continue its upward trend in the foreseeable future. Overall, Dexcom Inc‘s focus on continuous glucose monitoring systems for diabetes patients positions it well for long-term success in the medical device industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

Before it’s here, it’s on Smartkarma